Switch To Branded denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for switch to branded are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits the Quantity of the Branded Drug — and How to Appeal

Quantity limits on branded medications are among the most common restrictions Humana applies, even when a prior authorization has been approved. The plan sets a maximum number of units, tablets, patches, or fill days it will cover in a given period. For branded drugs that are dosed differently from their generic counterparts — or where a patient's prescribed regimen differs from the plan's standard limit — the authorized quantity may fall short of what the prescriber ordered.

## Why This Denial Is Appealable

Quantity limits must accommodate clinical necessity. If the FDA-approved prescribing information supports a dosing regimen that exceeds the plan's default limit, or if your prescriber has documented a clinical reason for the prescribed quantity (such as a titration schedule, a condition requiring higher frequency dosing, or a supply needed to prevent a gap in therapy), that is a reviewable medical basis for a quantity-limit exception.

Your federal appeal rights: - Internal appeal (ACA §2719 / ERISA §503): File within 180 days. The plan must evaluate your individual clinical circumstances, not simply restate the formulary limit. - External review: Available after internal exhaustion. The IRO window is generally up to four months from final internal denial. - Expedited review (72 hours): Available when the standard timeline would seriously jeopardize your health — relevant if a gap in therapy poses clinical risk.

## What to Gather

• Prescriber letter specifying the prescribed quantity and clinical rationale: Should cite the FDA-approved dosing range as the basis and explain why the prescribed quantity is medically necessary for your specific case.
• FDA prescribing label excerpt: Show the approved dosing range or schedule that supports the prescribed quantity.
• Humana's quantity-limit policy: Request the current criteria. Note whether a medical exception pathway exists and what documentation it requires.
• Clinical documentation supporting the regimen: Chart notes showing diagnosis severity, prior dose adjustments, or any condition-specific reason for the prescribed quantity.

## Criteria-Mapping Structure

| Humana Quantity-Limit Criterion | Supporting Documentation | |---|---| | Diagnosis requiring this drug | Diagnosis confirmation and clinical summary | | Prescribed quantity within FDA-approved range | FDA label excerpt + prescriber calculation | | Clinical reason for quantity exceeding default limit | Prescriber letter citing chart evidence | | [Exception pathway criterion] | Corresponding chart note or specialist support |

Your appeal letter should clearly state the quantity authorized, the quantity ordered, and the clinical basis for the difference. Attach the relevant section of the FDA prescribing information. If Humana upholds the limit, external review is your next step — IROs evaluate whether the limit is clinically appropriate for your individual case, not just whether it matches the plan's default.